我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
63
6 进行中
药物批准
10
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
2
3.2%
已完成
38
60.3%
尚未招募
4
6.3%
招募中
1.6%
终止
NMPA
National Medical Products Administration
- Japan's MHLW approved XEOMIN® (incobotulinumtoxinA) for cervical dystonia and blepharospasm, marking the fourth and fifth indications for the drug in Japan. - The approval was supported by Phase III trials conducted globally by Merz Therapeutics and locally by Teijin Pharma, including a 48-week Japanese blepharospasm study. - An estimated 28,000 people in Japan suffer from blepharospasm, with tens of thousands more affected by cervical dystonia, representing significant unmet need. - XEOMIN®'s purified formulation, free of complexing proteins, may reduce the risk of neutralizing antibody development during long-term repeat dosing.
